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Abstract: The preparation and characterization of ionic liquids and organic salts (OSILs) that
contain anionic penicillin G [secoPen] and amoxicillin [seco-Amx] hydrolysate derivatives and
their in vitro antibacterial activity against sensitive and resistant Escherichia coli and Staphylococcus
aureus strains is reported. Eleven hydrolyzed β-lactam-OSILs were obtained after precipitation in
moderate-to-high yields via the neutralization of the basic ammonia buffer of antibiotics with different
cation hydroxide salts. The obtained minimum inhibitory concentration (MIC) data of the prepared
compounds showed a relative decrease of the inhibitory concentrations (RDIC) in the order of 100
in the case of [C2OHMIM][seco-Pen] against sensitive S. aureus ATCC25923 and, most strikingly,
higher than 1000 with [C16Pyr][seco-Amx] against methicillin-resistant Staphylococcus aureus (MRSA)
ATCC 43300. These outstanding in vitro results showcase that a straightforward transformation of
standard antibiotics into hydrolyzed organic salts can dramatically change the pharmaceutical activity
of a drug, including giving rise to potent formulations of antibiotics against deadly bacteria strains.
Keywords: active pharmaceutical ingredients-ionic liquids and organic salts (API-OSILs); penicillin
G and amoxicillin hydrolysate derivatives; sensitive bacteria; resistant bacteria
1. Introduction
Bacterial resistance to antibiotics has been increasing in Europe over the last few years [1–3].
New classes of antibiotics have not been introduced recently [4–7], and, thus, more resistances to
old drugs are developing daily [8–10]. Recent efforts and huge investments being made in this field
by big pharma companies such as GlaxoSmithKline, Merck, Pfizer and Wyeth [3–5,11,12] have had
disappointing returns from their R&D departments, including clinical trials. This is a significant
factor to allocate anti-infective R&D resources into other fields of investigation and thus remain highly
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competitive [3–5,13]. Considering the disappointing results on genomics and the exodus of big pharma,
the problem of bacteria resistance has continued to evolve, reaching alarming dimensions [3,8,10].
For the last 12 years, organic salts and ionic liquids (OSILs) from active pharmaceutical ingredients
(APIs), or simply API-OSILs [14–22], have been studied at the academic level [14,18,19,23–25].
Ionic liquids (ILs) are salts with melting points below 100 ◦C (some of them are liquid at room
temperature) that result from the pairing of organic cations with organic and inorganic anions [14,20,23].
When the melting point is above 100 ◦C, these compounds are simply designated by organic salts [24].
Nowadays, there is a significant increase in the scope of both the physical and chemical properties of
OSILs [19,26–29], and, thus, their application in several topics of science and technology is currently
being studied [15–18,20,23,26].
In the case of API-OSILs, it is known that the interaction between an ionic API with selected
counter-ions may significantly improve the pharmaceutical activity of the former [17,30–32]. In addition,
this combination may also boost the stability and solubility of the API in physiological media, as
well as enhance the bioavailability and modify the pharmacokinetics and delivery mode of the
drug [21,27–29,33–35]. Consequently, the biopharmaceutics drug classification system (BCS) for
API-ILs can be significantly modified in comparison with the parent drugs [24], meaning that
this new salt of the old API can be treated as a new chemical entity and thus be independently
patented [17,26,30,36]. Furthermore, the polymorphism of a given API can be severely mitigated
or even eliminated if it becomes liquid, hence tackling one of the most important problems in the
pharmaceutical industry that can dramatically alter a drug’s solubility and dosages [26,30,37–40].
In fact, solid forms of drugs can suffer from several limitations such as low solubility, polymorphic
conversion, and low bioavailability [20,26,36,41].
The inherent properties of ILs could be of extreme importance to overcome such difficulties
of solid form drugs [20,36,41]. Recent works have shown that API-OSILs possess many attractive
properties when compared to conventional drugs [14,16,20,23]. Our group recently studied the relevant
pharmacological properties of ampicillin- and primaquine-based API-OSILs such as water solubility,
the octanol–water partition coefficient, the hexadecylphosphocholine (HDPC) micelle–water partition
coefficient, and critical micelle concentration [14–17,30]. In the case of ampicillin-based API-OSILs,
the data are clearly consistent with a greater potential of API-ILs in comparison with the parent API,
specifically regarding their solubility in water, as well as more specific properties such as membrane
affinity and permeation. In fact, the accurate selection of the organic cation allows for the fine-tuning
of some important physical and thermal properties like water solubility, membrane permeation,
melting point, and thermal stability [17]. In another study, we found that primaquine API-OSILs had a
particular affinity to intercalate negatively-charged lipid bilayers (membrane models of Plasmodium
infected erythrocyte) and also, to a lesser extent, zwitterionic lipid bilayers (membrane models of
healthy cells), in comparison with the parent drug [14,42].
A large quantity of recent communications and reviews have referred to the toxicity and activity
of ILs against microorganisms and cell cultures, especially antimicrobial activity, and as novel forms of
bioactive materials and as drug delivery systems [14,20,43–46]. Recently, OSILs have been studied to
fight multi-drug resistance [16,47] and as agents for microbial biofilms [32,45,48–51], and they have
shown a potent, broad spectrum activity against a variety of clinically significant microbial pathogens,
including methicillin-resistant Staphylococcus aureus (MRSA) [32,49,52]. The 2011 outbreak of multi
drug-resistant Escherichia coli O104 in Germany as well as as Gram-negative Enterobacteriaceae due to
presence of the New Delhi metallo-β-lactamase [53,54] are examples of an increasingly documented
major public health problem.
Therefore, there is an increasing demand to develop new drugs to address multi-resistant infections
and to develop more efficient tools so that new resistances are not developed. In this context, the results
up to this point given by API-OSILs have followed these demands [20].
Thus, following our work on ampicillin [16–18] and fluoroquinolone-based API-OSILs [30],
we herein describe the synthesis of ILs based on amoxicillin and penicillin G through a synthetic
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strategy that was optimized by us in the past for the preparation of ampicillin-OSILs [18]. The synthetic
method consists on the deprotonation of an API with different hydroxides of organic cations in
an ammonium buffer (buffer-controlled reaction procedure) [18]. In all cases, the antibiotic API is
combined as an anion with organic cations that contain imidazolium, ammonium, phosphonium and
pyridinium structures.
2. Results and Discussion
2.1. Chemistry
Ionic liquids and organic salts based on the ammonia hydrolysate anion of penicillin G and
amoxicillin (α-amide of benzyl penicilloic acid and of amoxicillin penicilloic acid, respectively),
abbreviated here as [seco-Pen] and [seco-Amx], respectively, were prepared by an ammonia buffer
reaction procedure that was recently developed by us for the synthesis of ampicillin API-OSILs [18].
Our original idea was to test a new method for preparation of API-OSILs based on parent penicillin
and amoxicillin in the anionic form. However, due to ammonolysis (β-lactam ring opening with the
formation of an amide group) of amoxicillin and penicillin G under the employed reaction conditions,
ionic liquids and organic salts of [seco-Pen] and [seco-Amx] anions were prepared instead (see Figure 1).
The prefix seco (Latin verb secare) is used in antibiotics nomenclature [55], and it means to cut.
Two penicilloic acids of penicillin G and amoxicillin are already well known in the literature [56–58],
and some of their stable amides—products of the amino- and ammonolysis of β-lactam ring of parent
antibiotics—have also already been described [59–61].
While amoxicillin (Amx) was used as provided (in trihydrate form), penicillin G, which was
supplied as a potassium salt ([K][Pen]), was previously converted to the corresponding ammonium
salt [NH4][Pen] by following the procedure of Brown et al. [62]. The experimental procedure consisted
on the reaction of hydroxide of the selected cations with amoxicillin and penicillin ammonium salt.
Halide (chloride, bromide) salts of selected organic cations were converted into the corresponding
hydroxides on Amberlite resin (OH form), and the highly basic solution that was obtained was then
added to the solution of the API in an aqueous ammonia buffer in order to provide the compounds [18].
[Na][seco-Amx] was prepared through a reaction with sodium hydroxide (instead of organic hydroxide),
while a [K][seco-Pen] derivative was directly obtained by ammonolysis from [K][Pen].
Hydrolyzed amoxicillin (seco-Amx) and penicillin G (seco-Pen) derivatives in the anionic form
were combined with the following organic cations (see Figure 1): 1-ethyl-3-methylimidazolium [EMIM],
1-hydroxy-ethyl-3-methylimidazolium [C2OHMIM], (2-hydroxyethyl)trimethylammonium [Choline],
tetraethylammonium [TEA], cetylpyridinium [C16Pyr] and trihexyltetradecylphosphonium [P6,6,6,14].
These cations were selected due to their low toxicity, except for [P6,6,6,14], which was chosen because it
usually produces room temperature ionic liquids (RTILs). Cetylpyridinium chloride is also already used
in some types of mouthwashes and toothpastes [53], although it is irritant in higher concentrations [54].
For control purposes in the biological activity studies, we also prepared the corresponding sodium and
potassium salts of the hydrolyzed antibiotics by following the same synthetic procedure.
The isolation of these compounds was performed similarly to the previously reported
ampicillin-based API-OSILs [18]. Briefly, the excess reactant was filtered-off after crystallization
from acetonitrile/methanol (9:1), and this was followed by solvent evaporation. Table 1 shows the
reaction yields, physical states and melting points of the prepared compounds. From the eleven
synthesized API-OSILs, two were organic salts and nine were ionic liquids, including four RTILs.
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Compound Yield Physical State Melting Point/°C 
[EMIM][seco-Amx] 77% Yellow solid 84–86 
[C2OHMIM][seco-Amx] 60% Yellow solid 109–111 
[P6,6,6,14][seco-Amx] 92% Yellow viscous liquid - 
[C16Pyr][seco-Amx] 94% Yellow solid 96–98 
Figure 1. Schematic synthetic methodology for the preparation of metallic active pharmaceutical
ingredients (API) salts and [seco-Amx] and [seco-Pen] ionic liquids and organic salts (OSILs).
The strict 1:1 cation–anion stoichiometry of the prepared API-OSILs, as well as the structural
integrity of both components, was confirmed by 1H NMR spectroscopy. Further characterization
was performed by 13C NMR and FTIR spectroscopies, as well as specific rotation, elemental analysis,
and mass spectrometry. The ammonolysis of the β-lactam rings of the original APIs was confirmed
by mass spectrometry. In the acquired electrospray ionization mass spectra (ESI-MS) spectra of all
analyzed API-OSILs in the negative mode, the base peak corresponded to [M + 17]− (m/z), which was
consistent with the β-lactam ring opening with the consequent formation of an amide group and a
secondary amine at the thiazolidine group.
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Table 1. Yield, physical state, and melting point of the synthesized API-OSILs.
Compound Yield Physical State Melting Point/◦C
[EMIM][seco-Amx] 77% Yellow solid 84–86
[C2OHMIM][seco-Amx] 60% Yellow solid 109–111
[P6,6,6,14][seco-Amx] 92% Yellow viscous liquid -
[C16Pyr][seco-Amx] 94% Yellow solid 96–98
[Choline][seco-Amx] 93% Yellow solid 143–144
[Na][seco-Amx] 96% Yellow solid 137–139
[EMIM][seco-Pen] 81% Colorless viscous liquid
[C2OHMIM][seco-Pen] 83% Yellow solid 48–50
[Choline][seco-Pen] 95% Yellow solid 69–71
[P6,6,6,14][seco-Pen] 97% Yellow viscous liquid -
[C16Pyr][seco-Pen] 89% Yellow solid 76–78
[TEA][seco-Pen] 90% Yellow viscous liquid -
[K][seco-Pen] 97% White solid 193–195
* This is a outside table footnote.
2.2. Biological Activity
In the present study, all prepared compounds were tested against several sensitive and resistant
Gram-positive and Gram-negative bacteria strains: Staphylococcus aureus ATCC 25923, Escherichia coli
ATCC 25922, methicillin resistant Staphylococcus aureus (MRSA ATCC 43300) and E. coli CTX M2 and
CTX M9.
The minimum inhibitory concentration (MIC) values were determined from three assays in
triplicate by the broth micro dilution method in a 96-well microtiter plate by using tryptic soy
broth (TSB) and adapted methodology from the Clinical Laboratory Standard Institute (CLSI) [62].
The strains were grown individually on tryptic soy agar for 24 h at 37 ◦C prior to each antibacterial
test. Preceding MIC determination, each inoculum density was adjusted in TSB to 0.5 McFarland
standards with a photometric device [62]. This resulted in a suspension that contained approximately
1 × 108 to 2 × 108 colony forming units (CFUmL−1) for E. coli ATCC25922® [60]. A similar approach
was used for the other strains. Then, 0.5 µL of the suspension was added to each well to have
5000–25,000 CFUmL−1. Bacteria were exposed to API-OSIL concentrations of 5, 2.5, 0.5, 0.05, 0.005,
0.0005, and 0.00005 mM. All compounds were dissolved in water except for OSILs that contained
[P6,6,6,14] and [C16Pyr] cations, which were diluted in 1% dimethyl sulfoxide (DMSO). Their activity was
determined in aqueous media, and the results of their activity were compared with bacteria that had
been grown in TSB broth in the presence of 1% DMSO. The MIC for each compound was recorded as
lowest molar concentration, showing no turbidity after 24 h of incubation at 37 ◦C [63,64]. The presence
of turbidity was an indication of microbial growth, and the corresponding concentration of antibacterial
agent was considered ineffective. The pharmacological activity of the prepared compound was then
compared to the parent commercial API in terms of the relative decrease of inhibitory concentration
(RDIC) as described earlier [16]. Herein, the RDIC value was calculated by dividing the MIC of the
commercial API (penicillin G potassium salt or amoxicillin trihydrate) by the MIC of the corresponding
synthesized compound.
2.3. Studies on Sensitive Bacteria
Table 2 shows data from the bioactivity study of the prepared compounds on S. aureus and E. coli
sensitive strains.
The data gathered in Table 2 show that, on a first approach, the hydrolyzed salts of both Amx
and Pen lost all antimicrobial activity against the tested sensitive strains. In fact, this was true for
the vast majority of prepared OSILs. It has been a consistently and firmly established belief that
the antimicrobial activity of β-lactam antibiotics relies on the sacrificial action of these functional
groups [65] on transpeptidases that are responsible for the last cross-linking step of peptidoglycan
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synthesis in the bacterial cell wall. For that purpose, the transpeptidase active site (Ser residues in the
case of D, and D- and Cys residues in the case of L,D-transpeptidases) nucleophilically attacks the
nucleophilicity the carbonyl of the β-lactam ring, resulting in its opening of the ring and the irreversible
formation of a covalent and stable acyl-enzyme complex [66,67]. However, this premise is widely
accepted but poorly demonstrated. Recently, it was shown that even the acylation reactions of Cys
residue of L,D-transpeptidases can be reversible, thus leading to limited antibacterial activity [68].
Table 2. Minimum inhibitory concentrations (mM) and relative decrease of inhibitory concentrations
(RDIC) of the new compounds that were produced on sensitive strains.
Compound S. aureusATCC25923 RDIC
E. coli
ATCC25922 RDIC
[EMIM][seco-Amx] 5.0 0.01 2.5 0.002
[C2OHMIM][seco-Amx] 0.050 1 5.0 0.001
[P6,6,6,14][seco-Amx] >5.0 <0.01 0.5 0.01
[C16Pyr][seco-Amx] >5.0 <0.01 0.050 0.1
[Choline][seco-Amx] >5.0 <0.01 >5.0 <0.001
Na[seco-Amx] >5.0 <0.01 >5.0 <0.001
Amx 0.050 1 0.005 1
[EMIM][seco-Pen] >5.0 <0.1 >5.0 <0.1
[C2OHMIM][seco-Pen] 0.005 100 >5.0 <0.1
[Choline][seco-Pen] >5.0 <0.1 5.0 0.1
[P6,6,6,14][seco-Pen] >5.0 <0.1 >5.0 <0.1
[C16Pyr][seco-Pen] >5.0 <0.1 >5.0 0.1
[TEA][seco-Pen] >5.0 <0.1 0.050 10
K[seco-Pen] >5.0 <0.1 >5.0 <0.1
K[Pen] 0.500 1 0.500 1
[EMIM][Br] 0.05 — >5 —
[C2OHMIM][Cl] >5.0 — 5.0 —
[P6,6,6,14][Cl] 2.5 — 2.5 —
[C16Pyr][Cl] 0.5 — 0.5 —
[Choline][Cl] 2.5 — >5.0 —
[TEA][Br] 2.5 — >5.0 —
The same result was obtained for the majority of the prepared salts, irrespective of the cation polarity,
resembling an ion trapping effect [69], i.e., ionic compounds such as [seco-Amx] and [seco-Pen] and their
conjugated acids are subject to a variety of processes, such as dissociation, electrical interactions with
organic matter, and changes in their partitioning in hydrophobic/hydrophilic media. These processes
depend on pH, ionic strength, their polarity, and pKa, and they ultimately lead to their accumulation
in certain zones of the bacterial cell, i.e., the ion-trap effect. On the other hand, highly polar cations
are more prone to closely interact with them in anionic form, anchoring them in the polar solution.
This effect has also been seen by us with ampicillin-based API-OSILs against sensitive Gram-positive
and Gram-negative species [16] and seem to adversely affect the activity of those compounds. In the
case of highly hydrophobic cations, the micelles of API-OSILs may be formed, thus reducing their
antimicrobial activity [70].
The only observed exceptions were [C2OHMIM][seco-Amx], [C2OHMIM][seco-Pen],
and [TEA][seco-Pen]. While the first one showed no advantage over Amx (RDIC = 1) against S. aureus,
the second and third seco-Pen OSILs recorded RDICs of 100 (S. aureus) and 10 (E. coli), respectively.
While inactive in the Cl− salt form, the [C2OHMIM]+ cation was the only selected cationic
entity that allowed for the enhancement of the antimicrobial activity of both seco-Amx and seco-Pen
against this sensitive S. aureus strain. These results most probably come from specific intermolecular
interactions between the cation and the anion, thereby enabling the deactivating interactions of crucial
PBPs. PBP:API-OSILs interaction studies will be conducted in the future and published accordingly.
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In the case of the sensitive Gram-negative E. coli strain, its outer membrane can hinder drug
delivery, as proposed above. In fact, the activity of [seco-Amx] and [seco-Pen] towards this strain did not
seem to be enhanced by the combination with [C2OHMIM] or with any of the other cations, with the
exception of [TEA] (RDIC = 10). In truth, [TEA][seco-Pen] was found to be ten times more effective
than the parent K[Pen]. These results are probably related with augmented hindrance of the porin
entrance and/or uncompetitive phase transfer delivery through the outer membrane in comparison
with the free antibiotic.
Similar results were also recorded in a past study regarding ampicillin-based API-ILs with
sensitive Gram-positive and Gram-negative bacteria [16]. Recent results in the literature regarding
API-OSILs as antibiotics against sensitive bacteria have referred to discrete interactions with the bacteria
cell wall or membrane [71–79]. In particular, pyridyl cationic-modified benzylidene cyclopentanone
photosensitizers (PSs) that were developed by Wu et al. [77] showed that Gram-positive bacteria are
more sensitive than Gram-negative bacteria to photodynamic therapy because their walls are more
porous and all types of PSs can readily diffuse through them. In contrast, Gram-negative bacteria
possess an additional negatively charged outer layer that serves as a permeability barrier, so neutral
and anionic PSs often fail to effectively inactivate Gram-negative bacteria, while cationic PSs can
still strongly bind to their outer membrane and damage their integrity. In addition, antimicrobial
studies that were supported by FTIR spectroscopy experiments revealed that nalidixic acid salts
with particular ammonium cations exhibit enhanced antimicrobial activity against six different
Gram-negative Salmonella species and two nalidixic acid-resistant S. typhimurium strains by displaying
different modes of action towards proteins, carbohydrates, and lipids within the cell membrane [78].
One final example concerning FTIR bioassays revealed that hydrophobic N-alkyltropinium bromide
surfactants preferably interact with the fatty acids and amide groups within the cell envelope of
Gram-negative E. coli and with the peptidoglycan multilayer of the Gram-positive Listeria innocua
cells [79]. The interaction of the ILs based on penicillin and amoxicillin, as well as [seco-Pen] and
[seco-Amx] anions with the cell membrane of Gram-positive and Gram-negative bacteria strains, will be
studied soon and published accordingly.
2.4. Studies on Resistant Bacteria
The prepared OSILs from hydrolyzed amoxicillin and penicillin antibiotics were also studied
against resistant Gram-negative E. coli strains CTX M9 and CTX M2, as well as the methicillin-resistant
S. aureus ATCC 43,300 (see Table 3).
Table 3. Minimum inhibitory concentrations (mM) and and relative decrease of inhibitory concentration
(RDIC) of the new compounds that were produced on resistant strains.
Compound E. coli CTXM9 RDIC
E. coli CTX
M2 RDIC
MRSA
ATCC 43300 RDIC
[EMIM][seco-Amx] >5 - >5 - >5 -
[C2OHMIM][seco-Amx] >5 - > 5 - 5 >1
[P6,6,6,14][seco-Amx] 0.05 >100 1.0 >5 > 5 -
[C16Pyr][seco-Amx] 0.05 >100 0.05 >100 0.005 >1000
[Choline][seco-Amx] 0.5 >10 0.05 >100 0.5 10
Na[seco-Amx] >5 - >5 - >5 -
Amx >5 1 >5 1 >5 1
[EMIM][seco-Pen] >5 - >5 - >5 -
[C2OHMIM][seo-Pen] >5 - >5 - >5 -
[Choline][seco-Pen] 1.0 >5 >5 - 1.0 >5
[P6,6,6,14][seco-Pen] 0.5 >10 0.5 >10 >5 -
[C16Pyr]seco-[Pen] 0.5 >10 0.5 >10 0.05 >100
[TEA][seco-Pen] >5 - > 5 - >5 -
K[seco-Pen] >5 - >5 - >5 -
K[Pen] >5 1 >5 1 >5 1
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As expected, parent antibiotics (Amx and [K][Pen]), as well as the sodium and potassium salts
of their ammonia hydrolysates, were found to be inactive against all tested resistant bacteria strains.
For E. coli, five OSILs that contained the [seco-Amx] anion and three that contained the [seco-Pen]
anion showed increased activity (RDIC values between >5 and >100) against the parent antimicrobials.
The highest activity (RDIC > 100) was recorded for [C16Pyr][seco-Amx] against both resistant E. coli
strains, while [P6,6,6,14][seco-Amx] and [Choline][seco-Amx] were selective towards only one of the
strains—CTX M9 and CTX M2, respectively.
These results were somewhat similar to those regarding ampicillin-based API-OSILs against
resistant Gram-negative E. coli species that were previously described by us [16], where [C16Pyr][Amp]
and [P6,6,6,14][Amp] showed the highest antimicrobial activities of all compounds tested. Therein we
suggested that the drug delivery of the APIs is enhanced in some resistant E. coli strains by the
lipophilic counter-ions through the permeation of the outer layer. This postulation is supported by
results from other authors. More specifically, Vincent et al. [80] and Langgartner, J. et al. [81] similarly
demonstrated that transport across biological membranes bearing a highly polar anionic framework
can be facilitated if the APIs are paired with lipophilic ammonium ions that act as phase transfer
agents. Additionally, Rogers et al. [82] recently demonstrated on synthetic membrane models that
API-OSILs that contain lipophilic cations, preferably with established hydrogen bonds, exhibit an
increased membrane transport as compared to API-OSILs with weaker electrostatic interactions or even
traditional halide or metal salts. Finally, it is important to note that both hydrophobic and hydrophilic
ionic liquids have been recently studied as penetration enhancers [16,20,83,84]. Various nanocarriers can
serve as antimicrobial enhancers because they incorporate into lipid membranes or cell walls, leading to
membrane or wall disruptions in both Gram-positive and Gram-negative bacteria strains [77,85–91],
therefore increasing the drug’s efficiency.
The activity of prepared OSILs against the Gram-positive MRSA ATCC 43,300 strain seems even
more peculiar. IC50 values as low as 5 and 50 µM, respectively, were obtained with [C16Pyr][seco-Amx]
and [C16Pyr][seco-Pen], which corresponded to RDICs higher than 1000 and 100, respectively. The only
other measurable value was obtained with [Choline][seco-Pen] (RDIC > 5). In the former cases,
the contribution from the [C16Pyr] cation was unquestionable. Literature data [92] have shown that
the MIC for [C16Pyr][Cl] is five times higher in the methicillin-resistant than in methicillin-sensitive
S. aureus strains, suggesting that the contribution of this cation to the antibacterial activity of these
particular API-OSILs [92] is particularly significant as opposed to the parent antibiotics or their
hydrolyzed analogues (see Table 3). In other words, the amplified activity of [C16Pyr][seco-Amx]
and [C16Pyr][seco-Pen] can only be achieved due to a synergic effect of both ionic species. Such a
strong influence of [C16Pyr]+ seems quite in contrast with the unspecific activity of so-called enhancers
(such as [C2OHMIM]+ for sensitive S. aureus above) and prompt us to consider it as a β-lactam
antibiotic potentiator [63,72]. Similar results from the literature have shown that berberine in the
presence of ampicillin and oxacillin markedly lowers their MICs against MRSA despite berberine alone
exhibiting no bactericidal activity. Later, it was shown that, in fact, berberine affected MRSA biofilm
development and the dissemination of biofilm-associated infections [93,94]. This effect is most likely
related with the formation of salt bridges at an allosteric site of the PBP2a in MRSA ATCC 43300 [92].
Curiously, similar interactions were also found for another alkylpyridinium compound, namely the
antibiotic ceftaroline [95]. Thus, an analogous ionic allosteric effect at PBP2a may be occurring
with the described [C16Pyr]-based OSILs. Further studies, namely molecular dynamic and docking
simulations, must be performed in the future to confirm this assumption. Regardless of the mechanism,
the pronounced increase in RDIC values of the prepared API-OSILs, particularly against resistant
species, seems very interesting for a potential drug combination strategy. In spite of some controversy,
the combination of antimicrobials with non-active compounds may provide a quite promising strategy
to address the widespread emergence of antibiotic-resistant bacteria strains [96–98].
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3. Conclusions
The present work highlights that organic salts and ionic liquids that contain ammonia hydrolysates
of amoxicillin and penicillin G (seco-Amx and seco-Pen), in particular [C2OHMIM][seco-Amx],
[C2OHMIM][seco-Pen], [TEA][seco-Pen], [C16Pyr][seco-Amx], abd [Choline][seco-Amx],
[C16Pyr][seco-Pen] display a very strong antibacterial effect on sensitive and resistant E. coli
and MRSA strains, respectively. The gathered data suggest that the adequate ionic pairing of
such hydrolyzed antimicrobials with an ion-pair effect is vital to enhance or promote antibiotic
activity, with possible alterations in their mechanism of action according to the selected counter-ion.
In particular, the hydrophobic combination [C16Pyr][seco-Amx] demonstrated the highest efficiency
towards resistant bacteria strains, with particular emphasis to MRSA ATCC 43300. The combination of
[C16Pyr] with [seco-Pen] was also very effective against the latter. These results are clearly promising
and point towards a beneficial effect on the drug delivery of the modified APIs when combined with
hydrophobic organic cations. In this way, the antimicrobial resistance to these standard β-lactam
antibiotics can be drastically reduced in vitro.
Our results also show that future developments of novel APIs-OSILs must not only focus on the
toxicity and hydrophobicity of the counter ion—they must also look at the outcome. More specifically,
[P6,6,6,14][seco-Amp] follows the trend of [C16Pyr][Amp] on E. coli resistant strains, which suggests that
there may be other factors at stake to be considered.
The virtually limitless number of ionic pairs that can be assembled as API-OSILs makes this area
of research particularly interesting and potentially thriving. In addition, the straightforward synthetic
procedure adds virtually no barriers to its future industrial up-scaling and will thus eventually lead to an
effective combination therapy model to tackle the ever-emerging bacterial resistance towards antibiotics.
4. Experimental Section
4.1. Synthesis
Commercially available reagents were purchased from Aldrich, BDH—the Frilabo and Solchemar
laboratory reagents were used as received. The solvents were from Valente & Ribeiro and distilled
before use. Whenever necessary, the solvents were dried by standard procedures, distilled under
nitrogen and stored over molecular sieves.
The basic anion-exchange resin Amberlite IRA-400-OH (ion-exchange capacity 1.4 eq.mL−1) and
Amberlyst A-26 resins were purchased from Supelco. 1H and 13C-NMR spectra in (CD3)2SO, CD3OD
or D2O (from Euriso-Top) were recorded on a Bruker AMX400 spectrometer at room temperature
unless specified otherwise. To perform NMR, 5 mm borosilicate tubes were used, and the sample
concentration was, approximately, 7 mg/mL for 1H-NMR and 37 mg/mL for 13C-NMR. Chemical shifts
are reported downfield in parts per million (ppm).
ESI-MS were acquired with an API-ION TRAP(PO03MS), ITQB, Oeiras, Portugal, operating in
both positive- and negative ion modes and equipped with a Z-spray source. Source and desolvation
temperatures were 80 and 100 ◦C, respectively. The ionic liquid solutions in methanol at concentrations
∼10–4 mol dm−3 were introduced at a 10 µl min−1 flow rate. The capillary and the cone voltage
were 2600 and 25 V, respectively. Nitrogen was used as a nebulization gas and argon was used as a
collision gas. ESI-MS-MS were acquired by selecting the precursor ion with the quadrupole and then
performing collisions with argon at energies from 3 to 20 eV in the hexapole.
IR spectra were measured on a Perkin Elmer 683 by using KBr sample disks. Optical rotations
were recorded on a Perkin Elmer 241MC. The melting temperature (mT) was determined with a melting
point apparatus (Stuart Scientific). The elemental analysis experiments were performed in a CHNS
Series Thermo Finnigan-CE Instruments Flash EA 1112 under standard conditions (T combustion
reactor 900 ◦C, T GC column furnace 65 ◦C, multiseparation SS GC column, He2 flow 130 mL/min,
O2 flow 250 mL/min). The penicillin G potassium was transformed in penicillin G ammonium by the
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adaptation of the method of Salivar, C. J. et al. [63]. Figures 2–16 illustrate the chemical structures of all
prepared OSILs based APIs.
4.1.1. Synthesis of seco-Pen-Based OSILs
The preparation of ammonium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo
[3.2.0]heptane-2-carboxylate [NH4][Pen] was done as indicated by Salivar et al method.
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Salivar, C. J. et al. [63] before the reaction with hydroxide reactants.
Preparation of [NH4][seco-Pen]
Potassium penicillin (1 g; 2.6 mmol) was dissolved in 15 mL of a 1.0 M aqueous ammonium
solution. To the solution was added Amberlyst A-26 resin (5 eq.) that was previously stirred in a 2.0
M aqueous ammonium solution for 1 hour. The reaction mixture was stirred at room temperature
for an additional 1 h. The resin was filtered off, and the was solvent evaporated to provide the
desired product as a grey solid (0.828 g; 83%); 1H NMR (400 MHz, D2O) δ(ppm): 7.33–7.43 (m, 5H);
4.99 (d, J = 8 Hz, 1H); 4.81(s, 1H); 4.41 (d, J = 7.6 Hz, 1H); 3,69 (s, 2H); 3.50 (s, 1H); 1.56 (s, 3H);
1.25 (s, 3H); 13C NMR (100 MHz, D2O) δ(ppm): 177.55; 177.40; 176.65; 137.54; 132.14; 131.79; 130.22;
77.42; 67.24; 61.68; 60.93; 44.87; 29.56; 29.30.IR: υ = 3171; 2964; 1644; 1571; 1494; 1454; 1381; 1188; 1130;
1073; 1032; 784; 692; 502. Elemental analysis calculated for C16H24N4O4S·0.8H2O: C 50.19; H 6.74;
N 14.63. Found: C 50.11; H 6.67; N 14.97.
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Preparation of [K][seco-Pen]
Potassium penicillin (0.137g; 0.36 mmol) was dissolved in a 1.0 M aqueous ammonium solution.
The mixture was stirred at room temperature for 4 h. The solvent was evaporated to provide the
desired product as a yellow solid (0.139 g; 97%); m.p. 193–195 ◦C; 1H NMR (400 MHz, D2O) δ(ppm):
7.34–7.44 (m, 5H); 4.98 (d, J = 7.6 Hz, 1H); 4.83 (t, J = 1.6 Hz, 1H); 4.39 (d, J = 8 Hz, 1H); 3.70 (s, 2H);
3.47 (s, 1H); 1.57(s, 3H); 1.25 (s, 3H); 13C NMR (100 MHz, D2O) δ(ppm): 177.82; 177.44; 176.79;
137.56; 131.77; 132.13; 130.19; 77.58; 67.42; 62.05; 61.20; 44.85; 29.49; 29.37; IR: υ = 3288; 2969; 2925;
1648; 1582; 1496; 1454; 1382; 1364; 1257; 1128; 877; 791; 694; 502. Elemental analysis calculated for
C16H20KN4O5S·3H2O: C 44.22; H 5.80; N 9.67. Found: C 44.45; H 5.54; N 9.70.
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Figure [seco-Amx].
Preparation of [TEA][seco-Pen]
Tetraethylammoniu bromide (0.420 g; 2.00 mol) was dissolved in ethanol and passed
through Amberlite IRA-400-OH an ion-exchange column [18,99] (5 eq., flux rate 0.133 mLmL−1min−1
= 8 BVh−1). Then, the tetraethylammonium hydroxide solution that was formed was slowly added to
the ammonium penicillin G (0.75 g; 2.14 mmol) that was dissolved in the 1.0 M aqueous ammonium
solution (50 mgmL−1). The reaction mixture was stirred at room temperature for 1 h. After solvent
evaporation, the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] an left
refrigerated overnight (4 ◦C) [18,99] to induce the precipitation of the excess of reagents. When the
reagent crystals were filtered out, the solution was evaporated, and the rest was dried in a vacuum
for 24 h to provide the desired product as a yellow viscous liquid (0.856 g; 90%). [α]D25 = 104.0 ± 6.1
(c = 2 mgmL−1 in methanol), 1H-NMR (400.13 MHz, CD3OD) δ = 7.31–7.22 (m, 5H), 5.46 (s, 1H),
4.17 (s, 1H) 3.70 (s, 1H), 3.63-3.58 (m, 2H), 3.51 (bs, 1H), 3.27–3.26 (m, 8H), 1.63 (s, 3H), 1.55 (s, 3H),
1.30–1.24 (m, 12H); 13C-NMR (100.62 MHz, CD3OD) δ = 174.72, 174.37, 174.15, 140.88, 136.73, 130.31,
130.25, 129.63, 127.96, 75.73, 66.68, 60.19, 59.27, 53.29, 46.65, 43.83, 29.41, 28.67, 28.38, 27.66, 7.64 ppm;
IR (KBr): υ = 3420, 2981, 2924, 2862, 1840, 1736, 1721, 1648, 1560, 1543, 1490, 1459, 1432, 1396, 1367,
1173, 1130, 1053, 1027, 1001, 785, 734, 696, 619, 539 cm−1; (ESI+) m/z calculated for C8H20N+: 130.1
found 130.0; (ESI−) m/z calculated for C16H20N3O4S− 350.1 found 349.8.
Pharmaceutics 2020, 12, 221 12 of 23
Pharmaceutics 2020, 12, x 11 of 23 
 
60.93; 44.87; 29.56; 29.30.IR: υ = 3171; 2964; 1644; 1571; 1494; 1454; 1381; 1188; 1130; 1073; 1032; 784; 
692; 502. Elemental analysis calculated for C16H24N4O4S0.8H2O: C 50.19; H 6.74; N 14.63. Found: C 
50.11; H 6.67; N 14.97. 
Preparation of [K][seco-Pen] 
 
Figure 4. [K][seco-Pen] 
Potassium penicillin (0.137g; 0.36 mmol) was dissolved in a 1.0 M aqueous ammonium solution. 
The mixture was stirred at room temperature for 4 h. The solvent was evaporated to provide the 
desired product as a yellow solid (0.139 g; 97%); m.p. 193–195 °C; 1H NMR (400 MHz, D2O) δ(ppm): 
7.34–7.44 (m, 5H); 4.98 (d, J = 7.6 Hz, 1H); 4.83 (t, J = 1.6 Hz, 1H); 4.39 (d, J = 8 Hz, 1H); 3.70 (s, 2H); 
3.47 (s, 1H); 1.57(s, 3H); 1.25 (s, 3H); 13C NMR (100 MHz, D2O) δ(ppm): 177.82; 177.44; 176.79; 137.56; 
131.77; 132.13; 130.19; 77.58; 67.42; 62.05; 61.20; 44.85; 29.49; 29.37; IR:  υ = 3288; 2969; 2925; 1648; 1582; 
1496; 1454; 1382; 1364; 1257; 1128; 877; 791; 694; 502. Elemental analysis calculated for 
C16H20KN4O5S3H2O: C 44.22; H 5.80; N 9.67. Found: C 44.45; H 5.54; N 9.70. 
Preparation of [Na][seco-Amx] 
 
Figure 5. [Na][seco-Amx] 
Amoxicillin (0.127 g; 0.3 mmol) was dissolved in a 1.0M aqueous ammonium solution. After 20 
min, NaOH (0.012 g; 0.3 mmol) was added, and the mixture was stirred at room temperature for 4 h. 
The solvent was evaporated to provide the desired product as a yellow solid (0.127 g; 96%); m.p. 137–
139 °C; 1H NMR (400 MHz, D2O) δ(ppm): 7.30 (d, J = 8 Hz, 2H); 6.89 (d, J = 8.4 Hz, 2H); 4.35 (d, J = 7.2 
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Preparation of [P6,6,6,14][seco-Pen]
Trihexyl(tetradecyl)phosphonium chloride (1.000 g; 1.92 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400-OH [18,99] ion-exchange column (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the trihexyl(tetradecyl)phosphonium hydroxide solution that
was formed was slowly added to ammonium penicillin G (0.853 g; 2.43 mmol) and dissolved in a
1.0 M aqueous ammonium solution (50 mgmL−1). The mixture was stirred at room temperature for
1 h. After solvent evaporation, the residue was dissolved in a 20 mL solution (methanol/acetonitrile
1:9) [18,99] and left refrigerated overnight (4 ◦C) [14] to induce the precipitation of the excess reagent.
When the reagent crystals were filtered out, the solution was evaporated, and the rest was dried
in a vacuum for 24 h to provide the desired product as a yellow viscous liquid (1.560 g; 97%).
[α]D25 = 67.7 ± 3.0 (c = 2 mgmL−1 in methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 7.34–7.22 (m, 5H),
4.97 (1H, d, J = 6.7 Hz), 4.34 (dd, 1H, J = 6.7 Hz), 3.60 (d, 2H, J = 8.2 Hz), 3.50 (s, 1H), 2.20 (m, 8H),
1.56–1.25 (m, 54H), 0.96–0.88 (m, 12H) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 175.30, 174.83, 173.92,
136.76, 130.37, 129.59, 127.87, 76.81, 66.78, 60.14, 54.86, 43.68, 33.11, 32.19, 31.92, 31.84, 30.80, 30.51,
30.45, 29.91, 27.88, 23.77, 23.49, 22.36, 19.53, 19.05, 14.51, 14.38 ppm; IR (KBr): ν = 3308, 3028, 2951, 2923,
2853, 1737, 1669, 1607, 1536, 1496, 1456, 1418, 1379, 1262, 1201, 1113, 1031, 986, 860, 810, 761, 722, 694,
617, 454, 439, 424 cm−1; (ESI+) m/z calculated for C32H68P+: 483.4 found 483.8; (ESI−) m/z calculated for
C16H20N3O4S− 350.1, found 349.9.
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Then, the cetylpyridinium hydroxide solution that was formed was slowly added to ammonium
penicillin G (0.973 g; 2.77 mmol) that was dissolved in a 1.0 M aqueous ammonium solution
(50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation,
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated
overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals
were filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide
the desired product as a yellow solid (1.332 g; 89%). m.p. 76–78 ◦C; [α]D25 = 47.3 ± 3.6 (c = 2 mgmL−1
in methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 9.01 (d, 2H, J = 5.7 Hz), 8.59 (t, 1H, J = 7.8 Hz),
8.12 (t, 2H, J = 6.8 Hz), 7.33–7.21 (m, 5H), 4.95 (d, 1H, J = 7.1 Hz), 4.63 (t, 2H, J = 7.5Hz,), 4.35 (d, 1H,
J = 7.0 Hz), 3.60 (2H, d, J = 7.5 Hz), 3.50 (s, 1H), 1.56 (m, 3H), 1.42-1.09 (m, 31H), 0.90 (t, 3H, J = 6.6 Hz)
ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 175.16, 174.78, 173.98, 146.87, 146.00, 136.73, 130.40, 129.80,
129.60, 127.93, 76.34, 66.64, 63,15, 60.14, 43.67, 33.12, 32.55, 30.81, 30.67, 30.17, 27.86, 27.24, 23.78,
14.49 ppm; IR (KBr): δ = 3041, 3059, 2914, 2848, 1739, 1658, 167, 1601, 1542, 1528, 1508, 1487, 1472,
1397, 1368, 1322, 1270, 1209, 1177, 1128, 1078, 1032, 987, 960, 926, 818, 777, 716, 686, 619, 574, 475 cm−1;
(ESI+) m/z calculated for C21H38N+: 304.3 found 304.2; (ESI−) m/z calculated for C16H20N3O4S− 350.1,
found 349.9.
Procedure II
Cetylpyridinium chloride (0.145g; 0.43 mmol) was dissolved in methanol and was added Amberlyst
A-26 (3 eq.) The mixture was stirred for 1 h at room temperature. Then, the cetylpyridinium hydroxide
solution that was formed was slowly added to [NH4][seco-Pen] (0.150 g; 0.43 mmol) that was dissolved
in a 2.0 M aqueous ammonium solution, and the mixture was stirred at room temperature for 1 h.
The solvent was evaporated to p rovide the desired product as a white solid (0.263 g; 94%).
Preparation of [Choline][seco-Pen]
(2-hydroxyethyl)trimethylammonium chloride (0.277 g; 1.99 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the hydroxide solution that was formed was slowly added
to ammonium penicillin G (0.848 g; 2.41 mmol) that was dissolved in a 1.0 M aqueous ammonium
solution (50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation,
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated
overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals
were filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide
the desired product as a yellow solid (0.856 g; 95%). m.p. 69–71 ◦C; [α]D25 = 47.3 ± 3.6 (c = 2 mgmL−1
in methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 7.33–7.29 (m, 5H), 4.95 (d, 1H, J1 = 7.0 Hz),
4.35 (d, 1H, J1 = 7.0 Hz), 4.02–3.98 (m, 2H), 3.66–3.56 (m, 2H), 3.50-3.47 (m, 3H), 3.20 (s, 9H) 1.56 (s, 3H),
1.25 (s, 3H) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 174.72, 174.37, 174.15, 140.88, 136.73, 130.31,
130.25, 129.63, 127.96, 75.73, 69.06, 66.67, 60.20, 60.04, 59.53, 57.10, 46.65, 27.78, 27.47 ppm; IR (KBr): υ =
3468, 3074, 2966, 1652, 1496, 1479, 1461, 1396, 1356, 1279, 1204, 1131, 1083, 1054, 1010, 955, 887, 867, 796,
734, 702, 670, 620, 540, 476 cm−1; (ESI+) m/z calculated for C5H14NO+: 104.1, found 104.1; (ESI−) m/z
calculated for C16H20N3O4S− 350.1, found 349.9.
Pharmaceutics 2020, 12, x 13 of 23 
 
 
Figure 8. [C16Pyr][seco-Pen] 
Procedure I 
Cetylpyridinium chloride (0.822 g; 2.30 mmol) was dissolved in methanol and passed through 
an Amberlite IRA-400-OH ion-exchange column [18,100] (5 eq., flux rate 0.133 mLmL−1min−1). Then, 
the cetylpyridinium hydroxide solution that was formed was slowly added to ammonium penicillin 
G (0.973 g; 2.77 mmol) that was dissolved in a 1.0 M aqueous ammonium solution (50 mgmL−1). The 
mixture was stirred at room temperature for 1 h. After solvent evaporation, the residue was dissolved 
in a 20 mL solution (methanol/acetonitrile 1:9) [18,100] and left refrigerated overnight (4 °C) [18,100] 
to induce the precipitation of the excess reagent. When the reagent crystals were filtered out, the 
solution was evaporated, and the rest was dried in a vacuum for 24 h to provide the desired product 
as a yellow solid (1.332 g; 89%). m.p. 76–78 °C; [α]D25 = 47.3  3.6 (c = 2 mgmL−1 in methanol);1H-NMR 
(400.13 MHz, CD3OD) δ = 9.01 (d, 2H,J = 5.7 Hz), 8.59 (t, 1H, J = 7.8 Hz), 8.12 (t, 2H, J = 6.8 Hz), 7.33–
7.21 (m, 5H), 4.95 (d, 1H, J = 7.1 Hz), 4.63 (t, 2H, J = 7.5Hz,), 4.35 (d, 1H, J = 7.0 Hz), 3.60 (2H, d, J = 7.5 
Hz), 3.50 (s, 1H), 1.56 (m, 3H), 1.42-1.09 ( , 31H), 0.90 (t, 3H, J = 6.6 Hz) ppm; 13C-NMR (100.62 MHz, 
CD3OD) δ = 175.16, 174.78, 173.98, 146.87, 146.00, 136.73, 130.40, 129.80, 129.60, 127.93, 76.34, 66.64, 
63,15, 60.14, 43.67, 33.12, 32.55, 30.81, 30.67, 30.17, 27.86, 27.24, 23.78, 14.49 ppm; IR (KBr): δ = 3041, 
3059, 2914, 2848, 1739, 1658, 167, 1601, 1542, 1528, 1508, 1487, 1472, 1397, 368, 1322, 1270, 1209, 1177, 
1128, 1078, 1032, 987, 960, 926, 818, 777, 716, 686, 619, 574, 475 cm−1; (ESI+) m/z calculat d for C21H38N+: 
304.3 found 304.2; (ESI-) m/z calculated for C16H20N3O4S- 350.1, found 349.9. 
Procedure II 
Cetylpyridinium chloride (0.145g; 0.43 mmol) was dissolved in methanol and was added 
Amberlyst A-26 (3 eq.) The mixture was stirred for 1 h at room temperature. Then, the 
cetylpyridinium hydroxide solution that was formed was slowly added to [NH4][seco-Pen] (0.150 g; 
0.43 mmol) that was dissolved in a 2.0 M aqueous ammonium solution, and the mixture was stirred 
at room temperature for 1 h. The solvent was evaporated to p rovide the desired product as a white 
solid (0.263 g; 94%). 
Preparation of [Choline][seco-Pen] 
 
Figure 9. [Choline][seco-Pen] 
(2-hydroxyethyl)trimethylammonium chloride (0.277 g; 1.99 mmol) was dissolved in methanol 
and passed through an Amberlite IRA-400-OH ion-exchange column [18,100] (5 eq., flux rate 0.133 
mLmL−1min−1 = 8 BVh−1). Then, the hydroxide solution that was formed was slowly added to 
ammonium penicillin G (0.848 g; 2.41 mmol) that was dissolved in a 1.0 M aqueous ammonium 
solution (50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation, 
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,100] and left refrigerated 
Figure 9. [ li ][seco-Pen].
Pharmaceutics 2020, 12, 221 14 of 23
Preparation of [EMIM][seco-Pen]
1-ethyl-3-methylimidazolium bromide (0.578 g; 3.03 mmol) was dissolved in methanol and passed
through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate 0.133 mLmL−1min−1
= 8 BVh−1). Then, the hydroxide solution that was formed was slowly added to ammonium penicillin
G (1.11 g; 3.16 mmol) that was dissolved in an aqueous 1.0 M ammonium solution (50 mgmL−1).
The mixture was stirred at room temperature for 1 h. After solvent evaporation, the residue was
dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated overnight
(4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals were filtered
out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide the desired
product as a colorless viscous liquid (1.136 g; 81%). [α]D25 = 89.0 ± 7.0 (c = 2 mgmL−1 in methanol);
1H-NMR (400.13 MHz, CD3OD) δ = 8.99 (bs, 1H), 7.63 (s, 1H) 7.53 (s, 1H), 7.34–7.20 (m, 5H), 4.95 (d, 1H,
J = 7.0 Hz), 4.35 (d, 1H, J = 7.0 Hz), 4.24 (q, 2H, J = 7.3 Hz), 3.92 (s, 3H), 3.60 (d, 2H, J = 7.2 Hz),
3.50 (s, 1H), 1,60–1.50 (m, 6H), 1.25 (s, 3H) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 175.06, 174.83,
173.99, 136.80, 130.65, 130.39, 129.60, 127.90, 124.94, 123.25, 76.51, 60.13, 60.18, 60.11, 59.54, 46.02, 43.66,
36.51, 27.81, 27.65, 15.61 pm; IR (KBr): υ = 3468, 3368, 2970, 1660, 1540, 1501, 1456, 1395, 1456, 1395,
1354, 1300, 1258, 1169, 1131, 1301, 965, 918, 862, 828, 729, 700, 651, 620, 545 cm−1; (ESI+) m/z calculated
for C6H11N2+: 111.1, found 111.0; (ESI−) m/z calculated for C16H20N3O4S− 350.1, found 349.9.
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Preparation of [C2OHMIM][seco-Pen]
3-(2-hydroxyethyl)-1-methylimidazolium chloride (0.328 g; 2.03 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400(OH) ion-exchange column [14,41] (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the hydroxide solution that was formed was slowly added
to ammonium penicillin G (0.754 g; 2.14 mmol) that was dissolved in a 1.0 M aqueous ammonium
solution (50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation,
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated
overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals
were filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide
the desired product as a yellow solid (0.799 g; 83%). m.p. 48–50 ◦C; [α]D25 = 41.3 ± 6.0 (c = 2 mgmL−1 in
methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 8.98, (s, 1H), 7.61 (s, 1H), 7.54 (s, 1H), 7.33–7.21 (m, 5H),
4.94 (d, 1H, J = 7.1 Hz), 4.36 (d, 1H, J = 7.1 Hz), 4.29 (t, 2H, J = 4.9 Hz), 3.92, (s, 3H), 3.86 (t, 2H,
J = 4.9 Hz), 3.59 (d, 2H, J = 7.1 Hz), 3.50 (s, 1H), 1.55 (s, 3H), 1.24 (s, 3H) ppm; 13C-NMR (100.62 MHz,
CD3OD) δ = 175.04, 174.82, 174.00, 136.78, 130.63, 130.51, 130.40, 129.61, 129.85, 129.61, 127.91, 124.68,
124.00, 76.50, 66.76, 61.10, 60.12, 59.53, 53.26, 43.65, 36.45, 27.84 ppm; IR (KBr): υ = 3418, 2965, 2931,
2108, 1644, 1585, 1499, 1455, 1398, 1356, 1260, 1167, 1127, 1076, 1034, 879, 798, 734, 704, 668, 619, 464,
445, 432, 424 cm−1; (ESI+) m/z calculated for C6H11N2O+: 127.2, found 127.0; (ESI−) m/z calculated for
C16H20N3O4S− 350.1, found 349.9.
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4.1.2. Synthesis of seco-Amx-Based OSILs
Preparation of [EMIM][seco-Amx]
1-ethyl-3-methylimidazolium chloride (0.385 g; 2.01 mmol) was dissolved in methanol and passed
through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate 0.133 mLmL−1min−1
= 8 BVh−1). Then, the hydroxide solution that was formed was slowly added to amoxicillin trihydrate
(0.930 g; 2.22 mmol) that was dissolved in an aqueous 1.0 M ammonium solution (50 mgmL−1).
The mixture was stirred at room temperature for 1 h. After solvent evaporation, the residue was
dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated overnight
(4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals were filtered
out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide the desired
product as a yellow solid (0.768 g; 77%). m.p. 84–86 ◦C; [α]D25 = 48.3 ± 5.0 (c = 2 mgmL−1 in methanol);
1H-NMR (400.13 MHz, CD3OD) δ = 7.64 (s, 1H), 7.56 (s, 1H), 7.27 (d, 2H, J = 8.2 Hz), 6.74 (d, 2H,
J = 8.4 Hz), 5.00 (d, 1H, J1 = 5.9 Hz), 4.74 (s, 1H), 4.30 (d, 1H, J1 = 5.9 Hz), 4.25 (1, 2H, J = 7.3 Hz),
3.77 (bs, 1H), 3.92 (s, 3H), 3.73, (bs, 1H), 3.43 (bs, 1H), 3.35 (s, 1H, s), 1.55–1.48 (m, 6H); 1.22 (s, 3H)
ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 175.57, 175.15, 174.84, 141.24, 129.83, 129.12, 128.50, 124.96,
123.31, 77.12, 66.67, 60.18, 60.11, 59.54, 46.03, 36.46, 27.78, 27.47, 15.63 ppm; IR (KBr): υ = 3461, 2921,
2852, 1706, 1688,1656, 1636, 1560, 1541, 1508, 1461, 1403, 1348, 1260, 1170, 1130, 673, 620, 474, 422 cm−1;
(ESI+) m/z calculated for C6H11N2+: 111.1, found 111.0; (ESI−) m/z calculated for C16H21N4O5S− 381.1,
found 380.8.
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amoxicillin trihydrate (0.930 g; 2.22 mmol) that was dissolved in an aqueous 1.0 M ammonium 
solution (50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation, 
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,100] and left refrigerated 
overnight (4 °C) [18,100] to induce the precipitation of the excess reagent. When the reagent crystals 
were filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide 
the desired product as a yellow solid (0.768 g; 77%). m.p. 84–86 °C; [α]D25 = 48.3  5.0 (c = 2 mgmL−1 in 
methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 7.64 (s, 1H), 7.56 (s, 1H), 7.27 (d, 2H, J = 8.2 Hz), 6.74 
(d, 2H, J = 8.4 Hz), 5.00 (d, 1H, J1 = 5.9 Hz), 4.74 (s, 1H), 4.30 (d, 1H, J1 = 5.9 Hz), 4.25 (1, 2H, J = 7.3 Hz), 
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2852, 1706, 1688,1656, 1636, 1560, 1541, 1508, 1461, 1403, 1348, 1260, 1170, 1130, 673, 620, 474, 422 cm−1; 
(ESI+) m/z calculated for C6H11N2+: 111.1, found 111.0; (ESI−) m/z calculated for C16H21N4O5S- 381.1, 
found 380.8. 
Preparation of [P6,6,6,14][seco-Amx] 
Figure 12. [E I ][seco-Amx].
Preparation of [P6,6,6,14][seco-Amx]
Trihexyl(tetradecyl)phosphonium chloride (1.042 g; 2.01 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the trihexyl(tetradecyl)phosphonium hydroxide solution that
was formed was slowly added to amoxicillin (0.988 g; 2.36 mmol) that was dissolved in a 1.0 M aqueous
ammonium solution (50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent
evaporation, the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left
refrigerated overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. Then, the reagent
crystals were filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to
provide the desired product as a yellow viscous liquid (1.586 g; 92%). [α]D25 = 22.0 ± 5.8 (c = 2 mgmL−1
in methanol); (400.13 MHz, CD3OD) δ = 7.28 (d, 2H, J = 8.4 Hz), 6.76 (d, 2H, J = 8.4 Hz), 5.00 (d, 1H,
Pharmaceutics 2020, 12, 221 16 of 23
J = 5.9 Hz), 4.53 (s, 1H), 4.31 (d, 1H, J = 5.9 Hz), 3.42 (s, 1H), 2.23–2.16 (m, 8H), 1.60–1.22 (m, 54H),
0.95–0.88 (m, 12H) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 175.35, 174.22, 142.01, 129.62, 128.92,
116.59, 77.12, 66.57, 60.17, 54.94, 43.76, 33.18, 32.27, 31.93, 31.56, 30.89, 30.58, 30.01, 27.96, 23.85, 23.57,
22.45, 19.62, 19.15, 14.58, 14.46 ppm; IR (KBr): ν = 3419, 3921, 2107.38, 1638, 1560, 1506, 1459, 1398,
1270, 1130, 1000, 668, 619, 570, 476, 456, 433, 412 cm−1; (ESI+) m/z calculated for C32H68P+: 483.8 found
483.6; (ESI−) m/z calculated for C16H21N4O5S− 381.1, found 381.0.Pharmaceutics 2020, 12, x 16 of 23 
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Preparation of [C16Pyr][seco-Amx]
Cetylpyridinium chloride (0.456 g; 1.28 mmol) was dissolved in methanol and passed through an
Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate 0.133 mLmL−1min−1 = 8 BVh−1).
Then, the cetylpyridinium hydroxide solution that was formed was slowly added to amoxicillin (0.587
g; 1.40 mmol) that was dissolved in a 1.0 M aqueous ammonium solution (50 mgmL−1). The mixture
was stirred at room temperature for 1 h. After solvent evaporation, the residue was dissolved in a 20
mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated overnight (4 ºC) [18,99] to induce
the precipitation of the excess reagent. When the reagent crystals were filtered out, the solution was
evaporated, and the rest was dried in a vacuum for 24 h to provide the desired product as a yellow
solid (0.402 g; 52%). m.p. 96–98 ◦C; [α]D25 = 77.0 ± 5.8 (c = 2 mgmL−1 in methanol); 1H-NMR (400.13
MHz, CD3OD) δ = 8.98 (d, 2H, J = 5.8 Hz), 8.58 (t, 1H, J = 7.74 Hz), 8.10 (t, 2H, J = 6.7 Hz), 7.26 (d, 2H, J
= 8.5 Hz), 6.73 (d, 2H, J = 8.4 Hz), 5.01 (d, 1H, J = 6.0 Hz), 4.62 (t, 2H, J = 7.5 Hz), 4.46 (s, 1H), 4.30
(d, 1H, J = 6.0 Hz), 3.44 (s, 1H), 2.02, (t, 2H, J = 6.9 Hz), 1.48 (s, 3H), 1.38–1.26 (m, 28H), 1.22 (s, 3H)
0.90 (3H, t, J = 6.7 Hz) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 176.32, 175.60, 174.94, 158.32, 150.28,
146.87, 145.91, 132.86, 129.54, 116.55, 77.13, 66.61, 63,17, 60.14, 33.11, 32.53, 30.80, 30.67, 30.52, 30.16,
27.24, 23.77, 14.49 ppm; IR (KBr): υ = 3440, 2914, 2849, 1685, 1651, 1636, 1560, 1488, 1472, 1400, 1384,
1260, 1175, 1128, 847, 778, 720, 687, 621, 498, 476 cm−1; (ESI+) m/z calculated for C21H38N+: 304.3 found
304.4; (ESI−) m/z calculated for C16H21N4O5S− 381.1, found 380.9.
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Figure 14. [C16Pyr][seco-Amx].
Preparation [choline][seco-Amx]
(2-hydroxyethyl)trimethylammonium chloride (0.179 g; 1.28 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the hydroxide solution that was formed was slowly added
to amoxicillin (0.587 g; 1.40 mmol) that was dissolved in a 1.0 M aqueous ammonium solution
(50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation,
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the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated
overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals were
filtered out, the solution was evaporated, and the rest was dried in a vacuum for 24 h to provide the
desired product as a yellow solid (0.570 g; 93%). m.p. 143–144 ◦C; [α]D25 = 104.0 ± 3.4 (c = 2 mgmL−1
in methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 7.36 (d, J = 8.1 Hz, 2H), 6.93 (d, J = 8.1 Hz, 2H),
5.06 (d, J = 6.8 Hz, 1H), 4.64 (s, 1H), 4.40 (d, J = 6.8 Hz, 1H), 4.13–4.04 (m, 2H), 3.53 (t, J = 4.6 Hz, 2H),
3.37 (s, 1H), 3.22 (s, 9H), 1.46 (s, 3H), 1.24 (s, 3H) ppm; 13C-NMR (100.62 MHz, CD3OD) δ = 176.14,
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Preparation of [C2OHMIM][seco-A x]
3-(2-hydroxyethyl)-1-methylimidazolium chloride (0.456 g; 1.28 mmol) was dissolved in methanol
and passed through an Amberlite IRA-400-OH ion-exchange column [18,99] (5 eq., flux rate
0.133 mLmL−1min−1 = 8 BVh−1). Then, the hydroxide solution that was formed was slowly added
to amoxicillin (0.525 g; 1.44 mmol) that was dissolved in a 1.0 M aqueous ammonium solution
(50 mgmL−1). The mixture was stirred at room temperature for 1 h. After solvent evaporation,
the residue was dissolved in a 20 mL solution (methanol/acetonitrile 1:9) [18,99] and left refrigerated
overnight (4 ◦C) [18,99] to induce the precipitation of the excess reagent. When the reagent crystals
were filtered from the solution, the solution was evaporated, and the rest was dried in a vacuum for 24 h
to provide the desired product as a yellow solid (0.359 g; 60%). m.p. 109–111 ◦C; [α]D25 = 47.3 ± 3.6
(c = 2 mgmL−1 in methanol); 1H-NMR (400.13 MHz, CD3OD) δ = 7.61 (s, 1H), 7.55 (s, 1H), 7.27 (d, 2H,
J = 8.4 Hz), 6.74 (d, 2H, J = 8.4 Hz), 5.00 (d,1H, J = 6.0 Hz), 4.47 (s, 1H), 4.30–4.27 (m, 3H), 3.92 (s, 3H),
3.86 (t, 2H, J = 4.86 Hz), 3.43 (s, 1H), 1.48 (s, 3H), 1.22 (s, 3H) ppm; 13C-NMR (100.62 MHz, CD3OD)
δ = 176.33, 175.62, 174.95, 158.34, 132.89, 129.54. 124.75,124.04, 116.56, 77.17 66.64, 61.11, 60.15, 59.83,
59.50, 53.81, 36.45, 27.78, 27.47 ppm; IR (KBr): υ = 3420, 2970, 2921, 1722, 1690, 1655, 1599, 1577, 1545,
1509, 1436, 1386, 1322, 1251, 1170, 1132, 1108, 1067, 877, 840, 820, 778, 652, 621, 535, 474 cm−1; (ESI+)
m/z calculated for C6H11N2O+: 127.2, found 127.0; (ESI−) m/z calculated for C16H21N4O5S− 381.1,
found 380.9.
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